Hugel to Present at 'JP Morgan Healthcare Conference'... Introducing Blueprint for Global Market Expansion

[Asia Economy Reporter Hyunseok Yoo] Hugel announced on the 6th that it will participate in the '38th JP Morgan Healthcare Conference' held in San Francisco, USA, from the 13th to the 16th (local time) to present its domestic and international business status and future vision.

Now in its 38th year, the JP Morgan Healthcare Conference is the world's largest healthcare conference, with about 1,500 pharmaceutical and biotech companies from approximately 40 countries worldwide participating annually. As many leading domestic and international pharmaceutical and biotech companies attend, it is recognized as an authoritative event related to the global pharmaceutical and biotech industry, with participating companies achieving tangible results at each conference while grasping global market trends.

Hugel, which maintains the number one market share in the domestic botulinum toxin market, has been recognized for product excellence and corporate growth potential and will appear as a presenter in the 'Emerging Markets' track introducing major Asian companies at this year's conference. The presentation, starting at 10:30 AM on January 15 (local time), will be attended by key executives including CEO Jihoon Son, Head of Development Changjin Lee, and Head of Strategy Jihye Noh. They will introduce Hugel's competitiveness, which has achieved number one in the domestic botulinum toxin and HA filler markets and continues to grow steadily in overseas markets. Additionally, there will be presentations on Hugel's unique success factors, from the H.E.L.F academic forum to consumer-centered product development.

Hugel will also unveil its blueprint to become a global leader in the medical aesthetic field. With the acquisition of sales approval for botulinum toxin in China and upcoming submissions of BLA in the United States and Europe, Hugel plans to explain its corporate growth vision through overseas market expansion, R&D pipelines such as new formulation development, open innovation strategies, and production facility expansion as it prepares for full-scale entry into global big markets.

A Hugel official said, "We have been recognized for our competitiveness and growth potential not only in the domestic market but also overseas, enabling us to participate as a presenting company at the JP Morgan Healthcare Conference," adding, "We plan to introduce Hugel's corporate value and growth strategy into the global market to conference participants based on our expertise and customer trust."

This content was produced with the assistance of AI translation services.